Catalent said today that it launched an underwritten public offering for $250 million of its common stock to fund, in part, its $950 million purchase of biologics manufacturer Cook Pharmica.
In connection with the offering, Catalent is slated to grant underwriters a 3o-day option to buy up to $37.5 million of additional shares of common stock.
Get the full story at our sister site, Drug Delivery Business News.
The post Catalent floats $250m public offering to fund Cook Pharmica purchase appeared first on MassDevice.